SEC Form 4 · accession 0001445064-16-000193
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J. Romano
Officer — Sr. VP & Chief Scientific Ofcr
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 4, 2016 | A | 3,410 | $0.00 | A | 7,436 | D | |
| Ordinary SharesF2 | Jan 4, 2016 | A | 955 | $0.00 | A | 8,391 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F3 | $72.61 | Jan 4, 2016 | A | 22,288 | A | Jan 4, 2017 | Jan 4, 2026 | Ordinary Shares | 22,288 | 22,288 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning January 4, 2017.
- F2Represents restricted stock units that vest in three equal annual installments beginning January 4, 2017.
- F3The options vest in four equal annual installments beginning January 4, 2017.